Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That will be 3 with mine!!
FN
Ok!
We shall see!
Nano
All my apologies
I am at work. So I'm responding to you in between!
I am sure that she is very good at what she does!
But Seymour had more histories with NNVC.
And I know him. I don't know her!
FN
Yes I am at work I will later
Be patient!
Let me reframe it!
Nano told me that he will be happy to stop in the next few years
And I didn't know that!
I think that he is not old at all and it will be a shame for him to go!
He is the right Manager for NNVC!
FN
Are you calling me Weedie? Lol
I never said that!
Nano did!
I agree on his age and the fact that he wants to stop.
But if he wanted to continue, he is as competant if not better than other major CEO.
That's my opinion!
FN
Dr. Seymour is very competent as CEO for NNVC!
Dr. Eugene Seymour
Age Total Calculated Compensation This person is connected to 8 board members in 1 different organizations across 1 different industries.
See Board Relationships
73 $462,387
As of Fiscal Year 2013
Background*
Dr. Eugene Seymour, M.D., MPH, has been the Chief Executive Officer of NanoViricides, Inc. since June 8, 2005. Dr. Seymour served as the Chief Financial Officer of NanoViricides, Inc. since June 8, 2005 and also served as its Principal Accounting Officer. Dr. Seymour served as an Interim Chief Financial Officer of NanoViricides, Inc. since May 16, 2007. He began clinical practice in Internal Medicine and joined the UCLA Medical School faculty. He Left UCLA after two years and joined USC faculty as Associate Professor. He served in the Medical Corps of United States Army Reserve during the Vietnam era and attained the rank of Major. He was originally trained as a chemist, but decided to attend medical school in preparation for a career as a clinical investigator. In 1981, Dr. Seymour began treating patients with a strange new disease affecting primarily the gay population. He worked with a number of celebrity patients whose identity could not be disclosed for fear of being ostracized in the entertainment community. In 1986, he was requested by the United States government to establish a testing laboratory and run a large-scale surveillance program for HIV prevalence in the Hispanic population in Los Angeles. In 1989, he founded Saliva Diagnostic Systems Inc.and served as its Chief Executive Officer and President since 1993. He left SDS in 1996 to form a non-profit foundation, which funded both testing and training programs for health workers in Asia and Africa. Dr. Seymour served as a Consultant to the United Nations Global Program on AIDS and was sent to a number of different countries, (Lithuania, Latvia, Estonia, and Russia) to interact with local physicians and assist them in setting up testing programs. He served as the Chairman of NanoViricides, Inc. since June 8, 2005 and has been its Director since June 1, 2005. He served as a Director of Strategic Alliances at a medical education startup called Medschool.com. Dr. Seymour spends his time as a private investor evaluating evolving companies in the field of biotechnology. He is the holder of 8 issued patents. Following postgraduate medical training, he holds a Master's degree in the Epidemiology of Infectious Diseases at UCLA.
Collapse Detail
United States
Phone: 203-937-6137
Fax: --
Board Members Memberships*
2005-Present
Chief Executive Officer and Director
NanoViricides, Inc.
Education*
Master's Degree
University of California-Los Angeles
MD
University of California-Los Angeles
Other Affiliations*
University of California-Los Angeles
BioRevolution Capital Management LLC
Annual Compensation*
Salary $275,000
Total Annual Compensation $275,000
Stock Options*
Restricted Stock Awards $187,387
Exercisable Options 142,857
Total Number of Options 142,857
Total Compensation*
Total Annual Cash Compensation $275,000
Total Short Term Compensation $275,000
Other Long Term Compensation $187,387
Total Calculated Compensation $462,387
*Data is at least as current as the most recent Definitive Proxy.
Report Data Issue
Ads by Google
So this is not your stock!
Next!
TaTa, if I not mistaken, NNVC made you a happy investor, you sold well.
And if I recall you made a great leaving with trading the stock, so I don't understand why you want to live?
Did you make money yesterday morning?
Off all of us you might the one who has the smarter playing that game !
Why would you live a great opportunity where you are already successful ?
FN
That's a great surname Tata!!
After the investigation is finished the market should go back to normal.
Well I hope so.
FN
I doubt !
We are all part of the Nanofamily!
Thanks !!
When t saw you and Bob I had to join!
r2g2,
Thank you for your kind comments.
FN
The Short And Distort: Stock Manipulation In A Bear Market
By Rick Wayman on February 26, 2009 A A A
Filed Under: Bear Market, Enron, Financial Crime, Financial Industry Regulatory Authority, Market Manipulation, Recession, Short Selling
A less-publicized and more-sinister version of short selling can take place on Wall Street. It's called "short and distort" (S&D).
Nothing is inherently wrong with short selling, which is permissible under the regulations of the Securities and Exchange Commission (SEC). However, the S&D type of short seller uses misinformation and a bear market to manipulate stocks. S&D is as illegal as the pump and dump, but is mainly used in a bear market. It is important for investors to be aware of the dangers and to know how to protect themselves.
Shorters' Actions Can Promote a Healthy Market
Short selling is the practice of selling borrowed stock in the hope that the stock price will soon fall, allowing the short seller to buy it back for a profit. The SEC has made it a legal activity for several good reasons. First, it provides the markets with more information. Shorters (traders who practice selling short for a living) often complete extensive and legitimate due diligence to discover facts and flaws that support their suspicion that the target company is overvalued. Because most shorters are scrupulous and ethical, their actions are conducive to the health of the market. Finally, short selling also provides investors who own the stock (with "long" positions) with the ability to generate extra income by lending their shares to the shorts. (For background reading, see the Short Selling tutorial.)
S&D Traders Manipulate Stock Prices With Smear Campaigns
On the other hand, S&D traders manipulate stock prices in a bear market by taking short positions and then using a smear campaign to drive down the price of the targeted stock. This is the inverse version of the "pump and dump" tactic, whereby crooks buy stock (take a long position) and issue false information that causes the target stock's price to increase.
Generally, it is easier to manipulate stocks to go down in a bear market and up in a bull market. The pump and dump is better known than the S&D because of the long bull market and the media. For example, the stock market had been in a general uptrend in the early to mid 1980s, which provided ample fodder for "pumpers". Movies like "Wall Street" (1987) and "The Boiler Room"(2000) helped educate investors about the risk of this type of stock manipulation. (To read more about stock market movies, see Financial Careers According To Hollywood.)
The S&D shysters try to profit by stimulating fear, but this only works if they have credibility. As such, when working online they will often use screen names and email addresses that imply that they are associated with the SEC or the Financial Industry Regulatory Authority (FINRA) (formerly the National Association of Securities Dealers), or that they can regularly spot worthless stocks. Their goal is to convince investors that every proponent of the stock has ties to the company and that the SEC is watching and will halt the stock. S&Ds also intimate that they are looking out for investors' interests.
S&D players clutter message boards, so optimistic information cannot easily be found. "Get out before it all comes crashing down" and "Investors who wish to enter a class action lawsuit can contact…" are typical posts, as are their projections of $0 stock prices and 100% losses. If their strategy is suspected by "longs", they attack the person who has caught them. In other words, the market manipulator will do everything in his or her power to keep buyers out of the stock and keep the price heading south.
The Net Effect
When the short and distort maneuver succeeds, investors who initially bought stock at higher prices sell at low prices because of their mistaken belief that the stock is worthless, caused by an effective distortion campaign. At the same time, the S&Ds cover at low prices and lock in their gains.
Right after prominent bankruptcies such as Enron in 2001 or Nortel in 2009, investors could be more susceptible to this type of manipulation than during prosperous periods such as the 1990s in the U.S. During downturns, the first appearance of impropriety could cause investors to run for the hills much easier. As a result, many innocent, legitimate and growing companies could get burned, and investors along with them. (To learn about how you can profit when everyone else is heading for cover, read Profit From Panic Selling.)
How to Identify and Prevent S&D
Do not believe everything you read - verify the facts.
Do your own due diligence and discuss it with your broker.
Hypothecate your stock - take it out of its street name to prevent the short sellers from borrowing and selling it. (Learn more about doing your own due diligence in our related article, Due Diligence In 10 Easy Steps)
The best way to protect yourself is to do your own research. Many stocks with great potential are ignored by Wall Street. By doing your own homework you should feel much more secure in your decisions. And, even if the S&Ds attack your stock, you will be better able to detect their distortions and be less likely to fall prey to them by selling the stock at a loss.
How To Identify Good Research
Ask yourself these questions to spot the key characteristics of a good research report:
Get a Risk-Free $50k Practice Account at FOREX.com
1. Is There a Disclaimer?
The SEC requires that everyone providing investment information or advice fully disclose the nature of the relationship between the information provider (the research analyst) and the company that is the subject of the report. If there is no disclaimer, investors should disregard the report. (For related reading on disclosures, see Disclosures: The Good, The Bad, And The Ugly.)
2. What Is the Nature of the Relationship?
Investors can get good information from pieces published by investor relations firms, brokerage houses and independent research companies. Using all of these sources will provide information and perspectives that can help you make better investing decisions. However, you need to evaluate their conclusions in light of the compensation (if any) that the information provider received for the report.
Can a Wall Street analyst who is even partially compensated by trading generated by the report be more objective than a fee-based research firm that is paid a flat monthly rate with no "performance" bonus? The answer to this question is left for each investor to decide, but both reports are available to use for evaluating a potential investment. The nature of the compensation will provide information to help you evaluate a report's objectivity.
3. Is the Author Identified and Contact Information Provided?
Generally speaking, if the author's name and contact information are on the report, it is a good sign because it shows that the author is proud of the report, and provides investors with a way to contact the author for additional information.
Research reports from legitimate brokerage firms post the author's name and contact information near the top of the front page. If the author's name is not given, investors should be very skeptical of the report's contents.
4. What Are the Author's Credentials?
Letters after a name do not necessarily mean that the author of the report is a better analyst, but they do indicate that the analyst has undertaken additional studies to expand his or her knowledge of finance and investing. (For more insight, see The Alphabet Soup Of Financial Certifications.)
5. How Does the Report Read?
If the report contains grandiose words and exclamation points, beware. This not to say that good analysts are boring, but good reports don't read like the National Enquirer. A reputable analyst would never use exaggerations like "sure things" or "rockets", and would never suggest that you mortgage your home to buy a stock.
Objective research reports provide reasoned arguments to buy or sell a stock. Key factors such as management expertise, competitive advantages and cash flows are cited as evidence to support the recommendation. (For more insight, read Research Report Red Flags.)
6. Is There an Earnings Model and Target Price With Reasonable Assumptions?
The bottom line for any recommendation is the earnings model and target price. The assumptions upon which the earnings model is based should be clearly stated so the reader can evaluate whether the assumptions are reasonable. The target price should be based on valuation metrics - such as the price-to-earnings (P/E) or price-to-book (P/B) ratio - that are also based on reasonable assumptions. If a report lacks these details, it is generally safe to assume that the report lacks a sound basis, and should be ignored.(For more details about analyzing ratios, see the Financial Ratio Tutorial.)
7. Is There Ongoing Research Coverage?
A commitment to providing ongoing research coverage (at least one report per quarter for at least one year) indicates that there is a solid belief in the company's fundamental strengths. It takes a lot of resources to provide this type of coverage, so a firm providing ongoing coverage is a sign that it legitimately believes in the long-term potential of a stock.
This contrasts with one-time reports that are used to manipulate stocks. In these cases, supposed research firms will suddenly issue "reports" on stocks they have never reported on before. Generally, these reports can be identified as an attempt at stock manipulation because they will not contain the attributes of a legitimate research report (discussed above).
The Bottom Line
Unscrupulous short and distort tactics can leave investors holding the bag. Fortunately, high-quality stock reports are relatively easy to spot, and needn't be confused with stock manipulators' dramatic claims. Keep your cool when analyzing a stock, and avoid getting caught up in online hype. By analyzing potential investments carefully and objectively, you can protect yourself from falling prey to S&D players - and make better stock picks overall.
Just the name "Pump Terminator" speaks for itself.
These are people who are looking to destroy small companies for their own good.
This is a severe case. If they are discovered, they will destroy themself.
FN
Good idea!
where is Bunny?
Teri Buhl or someone else can end up in jail after throwing such accusation.
specially if they are false.
I keep looking for my shotgun! Lol
This vicious Pump Terminator is creating a huge advertising on NNVC.
Thanks to him we might have a strong increase after the investigation.
Pump Terminator must feel very uncomfortable knowing that there are investigators
looking for him or them.
And, its arcticle not only helps the popularity of NNVC, but it puts an end to his evil ataques against honest company like nanoviricides.
A bad for a good!
FN
NanoViricides (NNVC) Responds to Short Seller
http://www.streetinsider.com/Management+Comments/NanoViricides+(NNVC)+Responds+to+Short+Seller/9152469.html
Article
Related Press Releases (1)
Related Articles (4)
Stock Quotes (1)
Comments (0)
FREE Breaking News Alerts from StreetInsider.com!
E-mail Address
Top News
Most Read
Highlighted
Market Wrap: Yellen Speaks, Markets Listen; Charter Firms on Time Warner Cable
After-Hours Stock Movers 2/11: (MRIN) (CUTR) (PHH) Higher; (PRGN) (FEYE) (CSOD) Lower (more...)
Stocks Lift as Yellen Takes a Dovish Tone
Procter & Gamble (PG) Updates on Venezuelan Impact; Lowers FY14 Core EPS Outlook
FireEye (FEYE) Tops Q4 EPS by 2c; Issues Weak FY14 Outlook
February 11, 2014 1:30 PM EST Send to a Friend
Get Alerts NNVC Hot Sheet
Price: $3.36 -23.98%
Trade NNVC Now!
Join SI Premium – FREE
NanoViricides, Inc. (NYSE: NNVC) responded to a baseless and inaccurate article posted on Seeking Alpha, a stock market analysis website, which obtains content from its member.
The article was filed anonymously by a person who identifies self as being short on NNVC stock and calls self "Pump Terminator". Clearly the person has vested interests. The article refers to a "Whistleblower Document" and "Smoking Gun" as the source of the information posted in the article. The source document is a serial complaint filed by a single shareholder in the United States District Court of Colorado, a complaint which the same shareholder brought three times in Nevada state court and which was dismissed twice and which has been amended a total of seven times. The Colorado Complaint had been previously dismissed and NanoViricides has moved to dismiss the current complaint again. Noteworthy is that the Plaintiff's attorney has asked the Colorado court to withdraw from the case.
Moreover, as it has done on each filing of the complaint, the Company denies the allegations in the complaint as well as the factual inconsistencies in the article. Each and every alleged covert and self-serving action was undertaken in compliance with all appropriate legal and disclosure requirements. Each transaction was believed to be fair and in the best interests of the Company's shareholders and reported by the Company in its filings with the Securities and Exchange Commission. In addition, the Company is always mindful of its expenditures and believes that the compensation paid to its officers to be reasonable and its costs to have been immensely conservative given the number of drugs the Company has developed in its pipeline.
Dr. Seymour, the founder and Chief Executive Officer of NanoViricides, stated, "We are outraged at this unfounded and intentional attempt at deflating the Company's stock price. We will have a more detailed response, in the near future, once we determine our options, including all legal action to determine the identity of the author, but we want to assure our shareholders and the market that the Company's purpose is the same as always - to eradicate life-threatening viruses and increase shareholder value."
Dr. Diwan, founder, President and Chairman of the Board commented, "This is a shameless attack from someone who neither understands the science nor the development work that has gone into nanoviricides® drug candidates. With very little money we have built a rich pipeline of drug candidates that are now getting closer to the clinic. I have personally taken high risks in making certain that the Company can continue to advance by undertaking the building of a highly specialized cGMP manufacturing facility at a time when NanoViricides did not have sufficient funds to be able to commit to this critical venture. All of the biological testing of our drug candidates is conducted by third parties. We are very happy to note that our drug candidates have been found to be safe and highly effective, and therefore worthy of clinical development."
Same here !
This is the company of a life time!
It's worth the risk! If or when they will break out, we will be proud to be the first owners of their stock!
Imagine the feeling when the stock will fly !
I think that the day after I will be so hung over !
FN
I wanted to said the speed of a missile
But you understood me!
Yes wait! You and others are going to be blown away!
The investors are out there ready to send that stock in to the moon at a missile speed! Wait and see!
FN
Good
Biotech stocks are doing very today!
ZF
I red a great article about NNVC that you wrote on Investor Village!
You should post it here also!
If you want of course !
Thanks for Being a great support !
FN
Thanks! An other great post !
2014 could be the trip to Hawaii !
FN
You need to change your name again!!
Exactly!
Monday is coming and we wait for "good news" that reflect progress on the road to clinical trials! Good news on Toxicology and Safety Studies could cause a gap up, possibly never to be filled again. How big a gap up?...hmmm, a gap up with impact commensurate to that of the "transformational technology" of NanoViricides, Inc.
Again, great post changes_iv !
Those news should come very soon!
And we should have a great Market's reaction!
FN
I love that on going conversation between you and Nano!
Yes ! You were waiting for the stock to recover!
They get paid!
We are getting there !!
they are planing their success!
That's a good question !
Logically it should go faster.
It's the same process for any viruses.
But this is a question for the FDA.
FN